|Bid||74.1700 x 100|
|Ask||74.2200 x 100|
|Day's Range||73.0400 - 74.3300|
|52 Week Range||42.6200 - 81.9100|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including a pharmacy operator's stock.
The U.S. Food and Drug Administration on Tuesday approved DexCom Inc's monitoring system to check blood sugar levels in children and adults suffering from diabetes, which can be used along with devices such as insulin pumps. This is the first glucose monitoring system permitted by the agency that can be used with other compatible medical devices, the FDA said. A previous version of DexCom's monitoring system had received FDA approval in 2016 but was not designed to be used with other devices.
On February 26, 2018, Medtronic (MDT) announced that the FDA has approved a new arm indication for its Guardian Sensor 3, the latest and most accurate CGM (continuous glucose monitoring) sensor. The expanded indication will enable the sensor to be worn on the upper arm, thus providing more flexibility, higher accuracy, and enhanced performance. It is the only sensor approved for use with Medtronic’s MiniMed 670G, which is the first HCL (hybrid closed loop) insulin delivery system in the world.
On February 21, 2018, Medtronic (MDT) announced the launch of its MiniMed Mio Advance infusion set, the newest addition to its portfolio of MiniMed infusion sets. The device is used for insulin delivery from an insulin pump to a person’s body. In late 2018, Medtronic plans to expand the commercial availability of the device in other geographies around the world.
The San Diego-based company said it had a loss of 11 cents per share. Earnings, adjusted for pretax expenses, were 10 cents per share. The results beat Wall Street expectations. The average estimate of ...
DexCom (NASDAQ: DXCM ) will be releasing its next round of earnings Tuesday. For all of the relevant information, here is your guide for today's Q4 earnings announcement. Earnings and Revenue Based on ...
The bulls that were plowing into Fitbit Inc (NYSE:FIT) headed into Thursday’s post-close earnings report are likely regretting that decision now. After gaining 5% during regular trading hours, Fitbit stock is now tanking the tune of 13% in pre-market action when disappointing results were underscored by even more disappointing guidance. No. If nothing else, Fitbit is a powerful brand name that will always be able to leveraged somehow.
DexCom Inc (NASDAQ:DXCM), a medical equipment company based in United States, saw significant share price volatility over the past couple of months on the NasdaqGS, rising to the highs ofRead More...
Fitbit shares dropped 13% in after-hours trading on Monday after the company missed on earnings and revenue for its fiscal fourth quarter.
The Soros Fund Management opened up smallish positions in the mid-cap biotechs DexCom and AnaptysBio in the most recent quarter.
Diverse product portfolio and strong veterinary business prospects to drive Patterson Companies (PDCO) in Q3. However, sluggishness in the Dental-Supply segment is a woe.
DexCom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like DexCom Inc (NASDAQ:DXCM), with a market cap of US$4.98B, are often out of the spotlight.Read More...
In fiscal 4Q17, Abbott Laboratories(ABT) invested ~6.9% of its total sales in R&D (research and development). In fiscal 2018, the company plans to invest ~7.5% of its total sales. Abbott Laboratories launched more than 20 new products in fiscal 2017. Abbott Laboratories now has an attractive product pipeline, boosted by the recent acquisitions—especially its acquisition of St. Jude Medical.
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018. The company reported sales growth across its three business segments: Pharmaceuticals, Medical Devices, and Consumer Businesses. The company’s medical device business contributed ~35% to J&J’s total sales in fiscal 4Q17.